{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:17:22Z","timestamp":1790273842621,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Neurobiology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.conb.2025.103150","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:50:53Z","timestamp":1766137853000},"page":"103150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Gene therapy for Parkinson\u2019s disease\u2014Ample room for optimism"],"prefix":"10.1016","volume":"96","author":[{"given":"Ivette M.","family":"Sandoval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-5487","authenticated-orcid":false,"given":"Fredric P.","family":"Manfredsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conb.2025.103150_bib1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, motor function, and motor milestones: Comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1","volume":"36","author":"Dabbous","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.conb.2025.103150_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.conb.2025.103150_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.crneur.2023.100086","article-title":"Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system","volume":"4","author":"Campos","year":"2023","journal-title":"Curr Res Neurobiol"},{"key":"10.1016\/j.conb.2025.103150_sref4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.conb.2025.103150_bib5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.omtm.2023.08.015","article-title":"Modifying immune responses to adeno-associated virus vectors by capsid engineering","volume":"30","author":"Bentler","year":"2023","journal-title":"Mol Ther, Methods Clin Dev"},{"key":"10.1016\/j.conb.2025.103150_bib6","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.conb.2025.103150_bib7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.conb.2025.103150_sref8","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1038\/s41591-025-03750-3","article-title":"AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial","volume":"31","author":"Butterfield","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.conb.2025.103150_sref9","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1016\/j.ymthe.2025.05.027","article-title":"Disease-modifying, multidimensional efficacy of putaminal Ca(V)1.3-shRNA gene therapy in aged parkinsonism male and female macaques","volume":"33","author":"Steece-Collier","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.conb.2025.103150_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102332","article-title":"Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS","volume":"35","author":"Sandoval","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.conb.2025.103150_bib11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/brain\/awaa020","article-title":"Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease","volume":"143","author":"Chu","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.conb.2025.103150_bib12","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/mds.29518","article-title":"Post-Mortem studies of neurturin gene therapy for Parkinson's Disease: two subjects with 10 years CERE120 delivery","volume":"38","author":"Chu","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103150_bib13","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.ymthe.2023.07.025","article-title":"Stowaways in the cargo: contaminating nucleic acids in rAAV preparations for gene therapy","volume":"31","author":"Brimble","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.conb.2025.103150_bib14","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41591-021-01522-3","article-title":"Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain","volume":"27","author":"Keiser","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.conb.2025.103150_sref15","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101295","article-title":"A self-complementary AAV proviral plasmid that reduces cross-packaging and ITR promoter activity in AAV vector preparations","volume":"32","author":"Taylor","year":"2024","journal-title":"Mol Ther, Methods Clin Dev"},{"key":"10.1016\/j.conb.2025.103150_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omtm.2019.06.006","article-title":"Neuronal activation stimulates cytomegalovirus promoter-driven transgene expression","volume":"14","author":"Back","year":"2019","journal-title":"Mol Ther, Methods Clin Dev"},{"key":"10.1016\/j.conb.2025.103150_bib17","first-page":"121","article-title":"Evaluation of site-specific methylation of the CMV promoter and its role in CHO cell productivity of a recombinant monoclonal antibody","volume":"5","author":"Dahodwala","year":"2022","journal-title":"Antib Ther"},{"key":"10.1016\/j.conb.2025.103150_bib18","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/mt.2009.196","article-title":"Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector","volume":"17","author":"Manfredsson","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.conb.2025.103150_bib19","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1002\/jcb.26608","article-title":"Ultrasound-triggered effects of the microbubbles coupled to GDNF- and Nurr1-loaded PEGylated liposomes in a rat model of Parkinson's disease","volume":"119","author":"Yue","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.conb.2025.103150_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12035-017-0728-7","article-title":"Intranasal administration of TAT-Conjugated lipid nanocarriers loading GDNF for Parkinson's Disease","volume":"55","author":"Hernando","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.conb.2025.103150_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s11671-024-04005-9","article-title":"Focused ultrasound on the substantia nigra enables safe neurotensin-polyplex nanoparticle-mediated gene delivery to dopaminergic neurons intranasally and by blood circulation","volume":"19","author":"Mascotte-Cruz","year":"2024","journal-title":"Discov Nano"},{"key":"10.1016\/j.conb.2025.103150_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12010072","article-title":"PLGA-PEG-ANG-2 nanoparticles for blood-brain barrier crossing: Proof-of-Concept Study","volume":"12","author":"Hoyos-Ceballos","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.conb.2025.103150_bib23","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1007\/s10571-023-01375-z","article-title":"Finding an optimal level of GDNF overexpression: insights from dopamine cycling","volume":"43","author":"Marshall","year":"2023","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.conb.2025.103150_bib24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/mds.27724","article-title":"Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease","volume":"34","author":"Heiss","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103150_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.24436","article-title":"Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial","volume":"78","author":"Warren Olanow","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.conb.2025.103150_bib26","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1074\/mcp.RA118.000680","article-title":"Glycomic and proteomic changes in aging brain nigrostriatal pathway","volume":"17","author":"Raghunathan","year":"2018","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.conb.2025.103150_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2023.114435","article-title":"Differential expression of RET and GDNF family receptor, GFR-alpha1, between striatum and substantia nigra following nigrostriatal lesion: a case for diminished GDNF-signaling","volume":"366","author":"Kasanga","year":"2023","journal-title":"Exp Neurol"},{"key":"10.1016\/j.conb.2025.103150_sref28","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105298","article-title":"GDNF signaling in subjects with minimal motor deficits and Parkinson's disease","volume":"153","author":"Chu","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2025.103150_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0331369","article-title":"GDNF receptor GFRalpha1 is necessary for the maintenance of dopaminergic neurons in the adult substantia nigra","volume":"20","author":"Carrier-Ruiz","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.conb.2025.103150_bib30","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1021\/acschemneuro.9b00291","article-title":"GFR-alpha1 expression in Substantia Nigra increases bilaterally following unilateral striatal GDNF in aged rats and attenuates nigral tyrosine hydroxylase loss following 6-OHDA nigrostriatal lesion","volume":"10","author":"Kasanga","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.conb.2025.103150_bib31","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s12035-013-8397-7","article-title":"Nigral GFRalpha1 infusion in aged rats increases locomotor activity, nigral tyrosine hydroxylase, and dopamine content in synchronicity","volume":"47","author":"Pruett","year":"2013","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.conb.2025.103150_bib32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fnmol.2020.00064","article-title":"alpha-Synuclein negatively regulates Nurr1 expression through NF-kappaB-Related mechanism","volume":"13","author":"Jia","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.conb.2025.103150_bib33","doi-asserted-by":"crossref","first-page":"14370","DOI":"10.1523\/JNEUROSCI.1155-15.2015","article-title":"Nurr1 and retinoid X receptor ligands stimulate ret signaling in dopamine neurons and can alleviate alpha-Synuclein disrupted gene expression","volume":"35","author":"Volakakis","year":"2015","journal-title":"J Neurosci"},{"key":"10.1016\/j.conb.2025.103150_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.nbd.2012.03.001","article-title":"Regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues","volume":"48","author":"Manfredsson","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2025.103150_sref35","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/mds.30193","article-title":"Intraputaminal delivery of Adeno-Associated virus serotype 2-Glial cell line-derived neurotrophic factor in mild or moderate Parkinson's Disease","volume":"40","author":"Van Laar","year":"2025","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103150_bib36","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/mds.27438","article-title":"Neurobiology of placebo effect in Parkinson's disease: what we have learned and where we are going","volume":"33","author":"Quattrone","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103150_bib37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/mds.27993","article-title":"Aromatic L-Amino acid decarboxylase gene therapy enhances levodopa response in Parkinson's Disease","volume":"35","author":"Nutt","year":"2020","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103150_bib38","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","article-title":"Safety of AADC gene therapy for moderately advanced parkinson disease: Three-Year outcomes from the PD-1101 trial","volume":"98","author":"Christine","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2025.103150_bib39","article-title":"VY-AADC Parkinson Disease Gene Therapy Program terminated","volume":"2025","author":"Hoffman","year":"2021"},{"key":"10.1016\/j.conb.2025.103150_bib40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/humc.2018.081","article-title":"Long-Term Follow-Up of a phase I\/II study of ProSavin, a lentiviral vector gene therapy for Parkinson's Disease","volume":"29","author":"Palfi","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.conb.2025.103150_bib41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.omtm.2019.07.002","article-title":"Gene therapy for Parkinson's Disease: preclinical evaluation of optimally configured TH:CH1 fusion for maximal dopamine synthesis","volume":"14","author":"Badin","year":"2019","journal-title":"Mol Ther, Methods Clin Dev"},{"key":"10.1016\/j.conb.2025.103150_bib42","series-title":"MDS virtual congress 2021","first-page":"2021","article-title":"Phase 1\/2 open-label dose evaluation study of AXO-Lenti-PD gene therapy for parkinson's disease: efficacy, safety, and tolerability data from the second cohort at 6 months [abstract]","volume":"vol. 36","author":"Corcoran Ak","year":"2021"},{"key":"10.1016\/j.conb.2025.103150_bib43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamasurg.2023.3852","article-title":"Real-time magnetic resonance imaging during convective gene therapy perfusion of the brain","volume":"159","author":"Akhter","year":"2024","journal-title":"JAMA Surg"},{"key":"10.1016\/j.conb.2025.103150_bib44","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/mt.2014.3","article-title":"Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo","volume":"22","author":"Cesana","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.conb.2025.103150_bib45","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-025-59113-6","article-title":"Deep brain stimulation alleviates Parkinsonian motor deficits through desynchronizing GABA release in mice","volume":"16","author":"Xu","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.conb.2025.103150_bib46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.conb.2025.103150_bib47","series-title":"MeiraGTx announces positive data from randomized, Sham-controlled clinical bridging study of AAV-GAD for the treatment of parkinson's disease","author":"Braco","year":"2024"},{"key":"10.1016\/j.conb.2025.103150_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau0713","article-title":"Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity","volume":"10","author":"Niethammer","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.conb.2025.103150_bib49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41531-025-00933-0","article-title":"Prioritizing Parkinson's disease risk genes in genome-wide association loci","volume":"11","author":"Lange","year":"2025","journal-title":"npj Parkinson's Dis"},{"key":"10.1016\/j.conb.2025.103150_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321145","article-title":"AAV delivery of GBA1 suppresses alpha-synuclein accumulation in Parkinson's disease models and restores functions in Gaucher's disease models","volume":"20","author":"Okai","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.conb.2025.103150_bib51","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103425118","article-title":"Wild-type GBA1 increases the alpha-synuclein tetramer-monomer ratio, reduces lipid-rich aggregates, and attenuates motor and cognitive deficits in mice","volume":"118","author":"Glajch","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.conb.2025.103150_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105432","article-title":"Alpha-synuclein and the Parkinson's disease drug pipeline","volume":"111","author":"Espay","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.conb.2025.103150_bib53","article-title":"Anti-Sense oligonucleotide as a therapeutic for synucleinopathies: pharmacokinetic, safety and efficacy evaluation","author":"Ahammad","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.conb.2025.103150_bib54","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.4103\/1673-5374.391190","article-title":"Unilateral rNurr1-V5 transgene expression in nigral dopaminergic neurons mitigates bilateral neuropathology and behavioral deficits in parkinsonian rats with alpha-synucleinopathy","volume":"19","author":"Gatica-Garcia","year":"2024","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.conb.2025.103150_bib55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamaneurol.2022.4193","article-title":"Abandoning the proteinopathy paradigm in parkinson disease","volume":"80","author":"Espay","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2025.103150_sref56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/M19-2534","article-title":"Isradipine versus placebo in early parkinson disease: a randomized trial","volume":"172","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.conb.2025.103150_bib57","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mds.28850","article-title":"Re-Analysis of the STEADY-PD II trial-evidence for slowing the progression of Parkinson's disease","volume":"37","author":"Surmeier","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103150_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm4560","article-title":"Ca(v)1.3 calcium channels are full-range linear amplifiers of firing frequencies in lateral DA SN neurons","volume":"8","author":"Shin","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.conb.2025.103150_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells9092045","article-title":"Calcium, bioenergetics, and Parkinson's disease","volume":"9","author":"Zampese","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.conb.2025.103150_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2024.102603","article-title":"The STRAT-PARK cohort: a personalized initiative to stratify Parkinson's disease","volume":"236","author":"Stige","year":"2024","journal-title":"Prog Neurobiol"}],"container-title":["Current Opinion in Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438825001813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438825001813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:24:59Z","timestamp":1775147099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959438825001813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":60,"alternative-id":["S0959438825001813"],"URL":"https:\/\/doi.org\/10.1016\/j.conb.2025.103150","relation":{},"ISSN":["0959-4388"],"issn-type":[{"value":"0959-4388","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for Parkinson\u2019s disease\u2014Ample room for optimism","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Neurobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conb.2025.103150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103150"}}